Tandem Stem Cell Transplantation for Non-Hodgkin's Lymphoma
Status:
Active, not recruiting
Trial end date:
2028-06-01
Target enrollment:
Participant gender:
Summary
This is a research study testing a new approach to treating high-risk non-Hodgkin's lymphoma
consisting of an autologous hematopoietic (blood) stem cell transplant (using a patient's own
hematopoietic cells) followed by a non-myeloablative allogeneic transplantation (transplant
from another individual).
The investigators hypothesize that the addition of the second non-myeloablative transplant
will improve the chances for long-term control of lymphoma.